The Psychedelics Newsletter, Issue 116

The UK’s emerging psychedelic healthcare industry

2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug development.?

The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medical treatments in the UK, has awarded Innovation Passports to psychedelic-assisted therapies to accelerate their time to market.

The UK is home to world-leading psychedelic research institutions and publicly traded companies, with direct access to London’s capital markets.

This lays the foundations for a domestic industry, with the PSYCH Symposium championing the emerging ecosystem.

READ MORE

EDUCATION NEEDED TO NORMALISE PSYCHEDELIC HEALTHCARE

Peter Reitano, CEO of Gwella, spoke to Psychedelic Health about the company’s mission to provide education on plant medicine for wellness.

READ MORE

TWO THIRDS OF CANADIANS BACK LEGALISATION OF?PSILOCYBIN

The poll, conducted by TheraPsil, found that 80% either approved or were ambivalent about the legalisation of psilocybin for medical purposes.

READ MORE

BUSINESS AND INVESTMENT

• Small Pharma reports?2022 financial results.
• A review of funding in?psychedelic medicine in 2022.
• The rise of ibogaine treatments for?opioid use disorder.
• Awakn to assess dissociative effects of?esketamine formulation.
• Psyence imports psilocybin?into the UK.
• The efficacy of psilocybin in the treatment?of cluster headaches.
• Small Pharma releases top-line results from?Phase II DMT trial.
• Psychedelic medicines?for addiction disorders.
• Filament Health receives approval for?clinical trial in Denmark.
• Why psilocybin could be used?therapeutically in Canada.
• Health Canada approves Diamond’s?Phase II psilocybin study.
• Algernon doses first patient with DMT?in stroke study.
• The efficacy of ketamine-assisted?therapy for couples.
• Apex Labs starts at-home psilocybin?trial for PTSD.

The market for ketamine-assisted therapy is expected to be worth over US$800 million in 2026.

The Psychedelics as Medicine Report: Fourth Edition?provides industry intelligence, empowering investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

SCIENCE AND RESEARCH

• Neuroimaging analyses impact of?MDMA therapy on PTSD.
• University of Colorado receives?US$2.1m for psilocybin study.
• Efficacy and safety of ketamine?in postoperative depression.
• Kernel shares data from?ketamine neuroimaging study.
• Over 65s more open to microdosing?than under 65s.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Early Bird tickets on sale for ￡299 + VAT.

TICKET REGISTRATION

REGULATION AND LEGISLATION

• Bill with bipartisan support?filed in Arizona.
• Legislature on psilocybin?services in Oregon.
• How psilocybin services would?work in Illinois.
• Veterans Affairs official asks for guidance?on psilocybin use.
• Oregon bill would expand state’s?intoxicated driving laws.

Would your organisation benefit from engaging with Europe's psychedelic medicine community?

Event partnership provides the opportunity to engage?with an?audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

• UK mental health services receive?￡150m in funding.
• The development of less toxic?alternatives to alcohol.
• UK recession could be worse?than previously expected.

?Do you know a spokesperson who could provide insights on the future of?psychedelic healthcare?

Previous?symposium?speakers include:?

• Rick Doblin - Founder, MAPS
• Cosmo Feilding Mellen?-?CEO, Beckley Psytech
• Carol Routledge?-?Chief Medical and?Scientific Officer, Small Pharma
• MP Crispin Blunt?- Chair, The Conservative Drug Policy Reform Group

SPEAKING OPPORTUNITIES